Bedaquiline is a diarylquinoline antimycobacterial drug and a key component of several
regimens in clinical development for the treatment of tuberculosis (TB) but with ongoing …

The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in
adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) …

Tuberculosis continues to be a major infectious disease burden worldwide. Increasing drug
resistance to first-line agents is making treatment more difficult. Bedaquiline is an orally …

Aims To externally validate an earlier characterized relationship between bedaquiline
exposure and decline in bacterial load in a more difficult‐to‐treat patient population, and to …

Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis
(MTB); moreover, 680,000 people developed multidrug-resistant TB (MDRTB). Methods …

Evaluation of: Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-
ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

Every year, the World Health Organization reports 500,000 new cases of drug-resistant
tuberculosis (TB), which poses a serious global danger. The increased number of XDR-TB …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …